四君子汤加减联合雷贝拉唑治疗慢性萎缩性胃炎的临床观察

Clinical observation on treating chronic atrophic gastritis with the Sijunzi decoction plus rabeprazole

目的:观察四君子汤加减联合雷贝拉唑治疗慢性萎缩性胃炎的临床效果。方法:选取我院2017年10月-2018年10月收治的慢性萎缩性胃炎患者100例,将其随机分为两组,各50例。采用雷贝拉唑治疗为对照组,基于此联合四君子汤加减治疗为观察组。比较两组治疗前后胃蛋白酶原比值(PGR)、胃蛋白酶原Ⅰ(Pepsinogen,PGⅠ)、胃泌素-17(Gastrin,GAS-17)等指标变化、疗效、不良反应以及生活质量。结果:在PGR、PGⅠ、GAS-17等指标方面,两组治疗前对比差异无统计学意义,P>0.05;而治疗后观察组各指标较对照组均显著增高,且差异有统计学意义,P<0.05。在治疗有效率方面,观察组(92.0%)较对照组(72.0%)明显较高,且差异有统计学意义,P<0.05。在不良反应方面,观察组发生率为6.0%,与对照组(10.0%)比较差异无统计学意义,P>0.05。在生活质量上,观察组各项评分较对照组均显著较高,且差异有统计学意义,P<0.05。结论:四君子汤加减联合雷贝拉唑治疗慢性萎缩性胃炎的疗效非常显著,即可有效改善临床症状和相关指标,且不良反应少,可提升患者生活质量,安全性较高,值得临床应用推广。

Objective: To observe the clinical efficacy of the Sijunzi decoction (四君子汤) plus rabeprazole on chronic atrophic gastritis. Methods: 100 patients with chronic atrophic gastritis admitted to our hospital from October 2017 to October 2018 were randomly divided into two groups, 50 cases in each. The control group was treated with rabeprazole, and the observation group was treated with Sijunzi decoction more. The changes of PGR, PGI, GAS-17 before and after treatment, efficacy, adverse reactions and quality of life were compared between the two groups. Results: There was no significant difference in PGR, PGI and GAS-17 between the two groups before treatment (P>0.05). After treatment, the indexes in the observation group were significantly higher than those in the control group, and there were no significant differences between the two groups (P>0.05). In terms of treatment efficiency, 92.0% in the observation group was significantly higher than 72.0% in the control group, and the difference was statistically significant (P<0.05). Adverse reactions were 6.0% in the observation group bette than 10.0% in the control group, P<0.05. In terms of quality of life, the scores in the observation group were significantly higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusion: The Sijunzi decoction plus rabeprazole has a remarkable effect on chronic atrophic gastritis. It can effectively improve the clinical symptoms and related indicators of patients, with fewer adverse reactions, and can improve the quality of life, which is worthy of clinical application and promotion.